Blog Layout

Predicting Medication Responses using Machine Learning Models

Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress

Rapid proliferation is a hallmark of cancer associated with sensitivity to therapeutics that cause DNA replication stress (RS). Many tumors exhibit drug resistance, however, via molecular pathways that are incompletely understood. Here, we develop an ensemble of predictive models that elucidate how cancer mutations impact the response to common RS-inducing (RSi) agents. The models implement recent advances in deep learning to facilitate multidrug prediction and mechanistic interpretation. Initial studies in tumor cells identify 41 molecular assemblies that integrate alterations in hundreds of genes for accurate drug response prediction. These cover roles in transcription, repair, cell-cycle checkpoints, and growth signaling, of which 30 are shown by loss-of-function genetic screens to regulate drug sensitivity or replication restart. The model translates to cisplatin-treated cervical cancer patients, highlighting an RTK–JAK–STAT assembly governing resistance. This study defines a compendium of mechanisms by which mutations affect therapeutic responses, with implications for precision medicine.


Link to full article

Share this Article with others

By Sorena Nadaf February 13, 2025
January 2025 Newsletter: The Year of Artificial Intelligence Sorena Nadaf-Rahrov, MS, MMI, PhDc
By Sorena Nadaf February 5, 2025
A recent Lancet study demonstrated that AI implementation led to a 29% increase in cancer detection, with no increase in false positives and a reduced workload compared to radiologists without AI assistance. While emerging evidence supports AI’s potential to enhance cancer detection in mammography screening and reduce screen-reading workload, further research is needed to fully understand its clinical impact.
By Sorena Nadaf December 10, 2024
Artificial intelligence to empower diagnosis of myelodysplastic syndromes by multiparametric flow cytometry
By Sorena Nadaf November 11, 2024
With heavy hearts, we remember and honor Brady Davis, whose sudden passing leaves an immense void. Brady was a devoted supporter and invaluable contributor to the Cancer Center Informatics Society, dedicating countless hours to advancing our mission and strengthening our community. His expertise, enthusiasm, and unwavering commitment shaped our initiatives and inspired everyone fortunate enough to work alongside him. Brady’s legacy will live on through the progress he championed and the connections he fostered. We extend our deepest sympathies to his family, friends, and all who knew him. He will be greatly missed. In honor of Brady’s legacy, Ci4CC will be forming a committee to explore meaningful ways to memorialize him within our society for years to come. We plan to announce the committee’s recommendations at our Spring Summit in San Diego, CA, on March 31, 2025. Please find his obituary here , and visit his memorial page on MyKeeper to leave a tribute. Support the Davis family in Brady’s memory via GoFundMe ---------- Cancer Center Informatics Society (Ci4CC) Sorena Nadaf-Rahrov & Warren Kibbe Co-Founders, Ci4CC
By Sorena Nadaf October 29, 2024
Nature Digital Medicine PRISM: Patient Records Interpretation for Semantic clinical trial Matching system using large language models
By Sorena Nadaf September 4, 2024
American Cancer Society and Color Health to Provide Free At-Home Colorectal Cancer Screening in Underserved Rural Communities
September 4, 2024
Leading Progress Against Cancer
August 24, 2024
By Drs Karen Knudsen & Othman Laraki.
By Sorena Nadaf July 18, 2024
Conversation with The Cancer Letter: NCI’s new chief data scientist Warren Kibbe tells us about efforts to get “AI-ready” - July 12, 2024
By Sorena Nadaf July 11, 2024
"Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, 2019" American Cancer Society
Share by: